These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22214393)

  • 81. Household members of persons with Alzheimer's disease: health conditions, healthcare resource use, and healthcare costs.
    Suehs BT; Shah SN; Davis CD; Alvir J; Faison WE; Patel NC; van Amerongen D; Bobula J
    J Am Geriatr Soc; 2014 Mar; 62(3):435-41. PubMed ID: 24576203
    [TBL] [Abstract][Full Text] [Related]  

  • 82. 2013 Alzheimer's disease facts and figures.
    Alzheimer's Association
    Alzheimers Dement; 2013 Mar; 9(2):208-45. PubMed ID: 23507120
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.
    Caro JJ; Salas M; Ward A; Getsios D; Mehnert A;
    Dement Geriatr Cogn Disord; 2002; 14(2):84-9. PubMed ID: 12145455
    [TBL] [Abstract][Full Text] [Related]  

  • 84. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.
    Whitehouse PJ; Winblad B; Shostak D; Bhattacharjya A; Brod M; Brodaty H; Dor A; Feldman H; Forette F; Gauthier S; Hay J; Henke C; Hill S; Mastey V; Neumann P; O'Brien B; Pugner K; Sano M; Sawada T; Stone R; Wimo A
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):266-80. PubMed ID: 9876955
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada.
    Getsios D; Caro JJ; Caro G; Ishak K;
    Neurology; 2001 Sep; 57(6):972-8. PubMed ID: 11571319
    [TBL] [Abstract][Full Text] [Related]  

  • 86. 2015 Alzheimer's disease facts and figures.
    Alzheimer’s Association
    Alzheimers Dement; 2015 Mar; 11(3):332-84. PubMed ID: 25984581
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
    Wimo A; Winblad B; Stöffler A; Wirth Y; Möbius HJ
    Pharmacoeconomics; 2003; 21(5):327-40. PubMed ID: 12627986
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2005; 23(2):193-206. PubMed ID: 15748093
    [TBL] [Abstract][Full Text] [Related]  

  • 89. 2016 Alzheimer's disease facts and figures.
    Alzheimer's Association
    Alzheimers Dement; 2016 Apr; 12(4):459-509. PubMed ID: 27570871
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.
    Caro J; Salas M; Ward A; Getsios D; Migliaccio-Walle K; Garfield F
    Drugs Aging; 2004; 21(10):677-86. PubMed ID: 15287825
    [TBL] [Abstract][Full Text] [Related]  

  • 91. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis.
    Kulasingam SL; Samsa GP; Zarin DA; Rutschmann OT; Patwardhan MB; McCrory DC; Schmechel DE; Matchar DB
    Value Health; 2003; 6(5):542-50. PubMed ID: 14627060
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The value of the managed entry of new drugs: a case study of donepezil.
    Payne K; Davies LM; Noyce PR; Weiss MC
    Int J Technol Assess Health Care; 2003; 19(1):114-28. PubMed ID: 12701944
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
    Pfeil AM; Kressig RW; Szucs TD
    Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Galantamine hydrobromide: an agent for Alzheimer's disease.
    Zarotsky V; Sramek JJ; Cutler NR
    Am J Health Syst Pharm; 2003 Mar; 60(5):446-52. PubMed ID: 12635450
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model.
    Hu S; Yu X; Chen S; Clay E; Toumi M; Milea D
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):565-78. PubMed ID: 26176750
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Ethical issues in Alzheimer's disease: an overview.
    Leuzy A; Gauthier S
    Expert Rev Neurother; 2012 May; 12(5):557-67. PubMed ID: 22550984
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study.
    Suh GH; Jung HY; Lee CU; Choi S;
    J Korean Med Sci; 2008 Feb; 23(1):10-7. PubMed ID: 18303192
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK.
    Zala D; Chan D; McCrone P
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):307-315. PubMed ID: 28612928
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Post-market utilization patterns of Alzheimer's disease treatments in South Korea: comparison with countries with universal health coverage.
    Lee HJ; Roughead EE; Han E; Lee J; Kalisch Ellett L
    Eur J Clin Pharmacol; 2021 Jun; 77(6):921-929. PubMed ID: 33409682
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The economic impact of Medicare Part D on congestive heart failure.
    Dall TM; Blanchard TD; Gallo PD; Semilla AP
    Am J Manag Care; 2013 May; 19(6 Suppl):s97-100. PubMed ID: 23725537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.